



NOV 26 2002

MORRISON & FOERSTER SAN DIEGO

0, 2001
J, 2001
TING BONE

Exhibit B: Marcus, Robert, Agents Affecting Calcification and Bone Turnover, The Pharmacological Basis of Therapeutics, 1519, 1540 (Hardman, et al., Eds., 1996)

- Exhibit C: Copy of Declaration of Gregory R. Mundy (7 pages)
- Exhibit D: Murray, et al., Exp. Cell Res. 242: 460-9 (1 page)
- Courtesy copies of previously cited references (70 references)
- Combined Declaration & Power of Attorney, unsigned (3 pages)
- Terminal Disclaimer (pages)
- 10. Petition for Correction of Inventor Name (2 pages)
- 11. Return Postcard

RECEIVED BY	THE UNITED	STATES	PATENT	AND	TRADEMARK	OFFICE
	ON	I				

RECEIVED

NOV 25 2002

U		
ME	Docket No.: 432722002622	
-	Gerial No.: 09/421,545	Atty: Laurie L. Hill/aeg Filing Date: October 20, 2001
	itle: INHIBITORS OF PROTEASOMAL AC	TIVITY FOR STIMUL MEDIC DORGO
<u>C</u>	GROWTH (AS AMENDED)	TON CENTED I
V	GROWTH (AS AMENDED) IA HAND DELIVERY ON NOVEMBER	19, 2002 via Courier 02/101/19 01
Dona	an analoga d	72 1/01/ 19 Pril 2: 19
	rs enclosed: Transmittal (1 page)	2:19
2.	Fee Transmittal (orig. & duplicate)	AVO
3.	Amendment, including Exhibit A: Version wit	h Markings of Changes Made (11 pages)
4. 1	exilloit b: Marcus, Robert, Agents Affecting (Calcification and Bone Turnover, The Pharmacological Ba
	Therapeutics, 1519, 1540 (Hardman, et al., Ed. Exhibit C: Copy of Declaration of Gregory R.	
o. t	Exhibit D: Murray, et al., Exp. Cell Res. 242: 4	460-9 (1 page) NOV o F 0000
/. (Courtesy copies of previously cited references	(70 references) NOV Z J ZUUZ
8. (9. 1	Combined Declaration & Power of Attorney, unferminal Disclaimer (insigned (3 pages) MORRISON & FOERSTER
· ·	Petition for Correction of Inventor Name (2	
10. F		DGE(3) . 7

Exhibit A

Docket No. 432722002

Massello

CERTIFICATE OF HAND DELIVERY

I hereby certify that this correspondence is being hand filed with the United States Patent and Trademark Office in Washington, D.

22

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Gregory R. Mundy, et al.

Serial Nos.: 09/113,947; 09/361,775; 09/421,545; 09/558,973 & 09/695,807

Filing Date:

For:

Examiner: R. Gitomer

Group Art Unit: 1623

COMMUNICATION

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Applicant greatly appreciates the Examiner's granting an interview and discussing the outstanding issues in connection with the above-identified applications. The following lists items to be hand-delivered to the Examiner in connection with each of the above-identified applications.

09/113,947 (Docket No. 432722002600)

Request for Reconsideration (including Exhibits A through F) sent to USPTO on October 19, 2001 via first class mail, on November 29, 2001 via hand-delivery and on January 2, 2002 via facsimile (without Exhibits A through E):

Exhibit A:

U.S. Patent No. 6,083,690;

Exhibit B:

U.S. Patent No. 6,022,887;

Exhibit C: WO 98/25460;

Exhibit D: Vinitsky, et al., Inhibition of the Proteolytic Activity of the Multicatalytic Proteinase Complex (Proteasome) by Substrate-related Peptidyl Aldehydes, J. Biol. Chem. 269(47): 29860 (1994); and

Exhibit E: Application Serial No. 09/096,631.

09/361,775 (Docket No. 432722002620)

Amendment and Response under 37 C.F.R. §1.116 (including Exhibits A through N) sent to USPTO on November 6, 2001 via hand-delivery, and a copy of a post card acknowledging USPTO's receipt of these references on November 6, 2001 is also included herein):

Exhibit A: A mark-up version of the amended claims 1-3;

Exhibit B: U.S. Patent No. 6,022,887

Exhibit C: U.S. Patent No. 6,117,887;

Exhibit D: U.S. Patent No. 6,075,150;

Exhibit E: U.S. Patent No. 5,847,076;

Exhibit F: Furet et al., *Bioorg. Med. Chem. Lett.*, <u>11(10)</u>:1321-4 (2001)

(Abstract only);

Exhibit G: Sunwoo et al., Clin. Cancer Res., 7(5):1419-28 (2001) (Abstract only);

Exhibit H: Sun et al., Cancer Res., 61(4):1280-4 (2001) (Abstract only);

Exhibit I: Princiotta et al., *Proc. Natl. Acad. Sci. U.S.A.*, 98(2):513-8 (2001) (Abstract only);

Exhibit J: U.S. Patent No. 6,207,458;

Exhibit K: Arnold et al., J. Biol. Chem., 276(18):14675-84 (2001) (Abstract only);

Exhibit L: Sharma et al., Bioorg. Med. Chem., 8(7):1819-23 (2000) (Abstract only);

Exhibit M: Ponnappan et al., Exp. Gerontol., 34(1):95-107 (1999) (Abstract only); and

Exhibit N: Li et al., J. Protein Chem., 17(8):757-63 (1998).

• references allegedly missing from the 3/13/00 IDS, namely References 1-4, 6, 9-25, 27-31, 33-41, 43-46, 48-59, 61-73, sent to USPTO on November 6, 2001 via hand-delivery (same references were also sent to USPTO on July 27, 2001 via first class mail with Amendment and Response under 37 C.F.R. §1.111, and a copy of a post card acknowledging USPTO's receipt of these references on August 1, 2001 is also included herein).

09/421,545 (Docket No. 432722002621)

- RESPONSE TO RESTRICTION REQUIREMENT AND PRELIMINARY AMENDMENT sent to USPTO on October 18, 2001 via first class mail.
- SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER
 37 C.F.R. § 1.97 with the PTO-1449 Form and references 1 and 5-8 sent to USPTO on September 7, 2001 via first class mail.

09/558,973 (Docket No. 432722002622)

- RESPONSE TO RESTRICTION REQUIREMENT AND PRELIMINARY
 AMENDMENT sent to USPTO on October 19, 2001 via first class mail.
- SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER
 37 C.F.R. § 1.97 with the PTO-1449 Form and references 1 and 5-8 sent to USPTO on September 7, 2001 via first class mail.

09/695,807 (Docket No. 432722002623)

- RESPONSE TO RESTRICTION REQUIREMENT sent to USPTO on December 17, 2001 via first class mail.
- INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 with the PTO-1449 Form and references 1, 10, 55, 63, 68 and 76 sent to USPTO on July 10, 2001 via first class mail.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to

charge the cost of such petitions and/or other fees due in connection with the filing of this document to <u>Deposit Account No. 03-1952</u> referencing docket no. <u>432722002630</u>. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated:

January 22, 2002

By:

Peng Chen

Registration No. 43,543

Morrison & Foerster LLP 3811 Valley Centre Drive

Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-5117 Facsimile: (858) 720-5125

CERTIFICATE OF MAILING VIA HAND-DELIVERY

annette Massella

Examiner: R. J. Gitomer

Group Art Unit: 1627

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

9 PH 2:18

In the application of:

Gregory R. Mundy, et al.

Serial No.:

09/421,545

Filing Date:

October 20, 1999

For:

INHIBITORS OF PROTEASOMAL

ACTIVITY FOR STIMULATING BONE

[AND HAIR] GROWTH (AS

AMENDED)

REQUEST FOR CORRECTION OF INVENTOR NAME

12/05/2002 GTRAHMEL 00000002 031952 09421545 PURSUANT TO 37 C.F.R. § 1.182

01 FC:1460

130.00 CH Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

The presently named applicants, Gregory R. Mundy, et al., hereby petitions the Assistant Commissioner to enter the Amendment of the application submitted herewith to provide a full name for the inventor G. Rossini. Enclosed are the following:

- 1. An oath or declaration by the actual inventor or inventors as required by § 1.63 or as permitted by §§ 1.42, 1.43 or § 1.47.
 - 2. The written consent of any assignee.
 - 3. The fee set forth in 37 C.F.R. § 1.17(h) of \$130.00.

- is enclosed
- X is authorized to be charged to **Deposit Account 03-1952**. A Fee Transmittal (form PTO/SB/17) is enclosed in duplicate for that purpose.

Applicant requests that the inventorship in the above-identified application be amended by adding the full first name of Jorge Gianny Rossini whose full first name was inadvertently omitted in the above application.

This request is supported by a Substitute Declaration, executed by Gregory R. Mundy, I. Ross Garrett, and Jorge Gianny Rossini. This amendment has been promptly filed as soon as the inadvertent typographical error was discovered in the above application.

The Patent and Trademark Office is respectfully requested to correct the inventorship and to enter the enclosed Substitute Declaration which has been executed by Gregory R. Mundy, I. Ross Garrett, and Jorge Gianny Rossini.

Bv

It is believed that applicant has complied with requirements and correction of the inventorship in the present application is respectfully requested.

Respectfully submitted.

Dated: November 18, 2002

Registration No. (51,804)

Morrison & Foerster LLP 3811 Valley Centre Drive

Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-7955 Facsimile: (858) 720-5125

RECEIVED
TECH FENTER 1600/2900

Please type a plus sign (+) inside this box → + Under the Paperwork Reduction Act of 199		02 NOV 19 PM 2:	\8 ent and Ti	Approved for use rademark Office; U.S	through 10/31/02	PTO/SB/21 (08-00) 2. OMB 0651-0031 T OF COMMERCE
/		Application Number	09/421,	ormation unless it dis	splays a válid Ol	MB control number.
TRANSMITTA	L	Filing Date	October 20, 1999		\(\frac{\chi}{\chi}\)	
FORM		First Named Inventor	Gregor	y R. MUNDY, et al.	_	"
		Group Art Unit	1627		1/0	Top O
(to be used for all correspondence after in	nitial filing)	Examiner Name	R. Gitomer		2 0-	
Total Number Of Pages In This Submission	31	Attorney Docket No.	4327220	002621		*
	ENCLOS	URES (check all that	apply	<u> </u>		
Fee Transmittal Form	Ass	signment Papers an Application)		After Allowance (Communicatio	n to Group
Fee Attached		wing(s)		Appeal Communi	ication to Boar	
Amendment / Reply (including Exhibit A: Version with Markings of Changes Made)	Lice	ensing-related Papers		Appeal Communi (Appeal Notice, Brie	ication to Grou	qı
After Final	Peti Inve	ition for Correction of entor Name		Proprietary Inform	nation (
Affidavits/declarations (unsigned) (3 pages)	Peti Prov	tion to Convert to a visional Application		Status Letter		,
Extension of Time Request	Pow Cha Add	ver of Attorney, Revocation nge of Correspondence ress	×	Other Enclosure(s	s) (please identii	fy below):
Express Abandonment Request	X Term	ninal Disclaimer	1	Calcification ar	cus, Robert, Age nd Bone Turnove cal Basis of Ther	er The
Information Disclosure Statement	Requ	uest for Refund	1	1540 (Hardmar Exhibit C: Copy	л, <i>et al</i> . Eds., 19: y of Declaration o	96) of Gregory R
Certified Copy of Priority Document(s)	CD,	Number of		Exhibit D: Exhibit	nt to 37 C.F.R. § bit D: Murray, et 9 (1 page) is of previously c	al., <u>Exp. Celi</u>
Response to Missing Parts/ Incomplete Application	Remarks			Sourcesy copie	s or previously d	ited references
Response to Missing Parts under 37 CFR 1.52 or 1.53						
5. O. V. 1.02 G. 1.00		25225				
		PATENT TI	RADEMARK (DFFICE		
		PPLICANT, ATTORNE	Y OR	AGENT		~
Firm or Laurie L. Hill, (Reg No 51,804) Individual Name Morrison & Foerster LLP 3811 Valley Centre Drive - Suite 500 San Diego, CA 92130-2332						
Signature Xauri X						
Date November 18, 2002						
hereby certify that this correspondence is being	ERTIFICATE (OF MAILING VIA HAND-DE	LIVERY			
hereby certify that this correspondence is being HAND-DELIVERED to the : Assistant Commissioner for Patents, Washington, D.C. 20231, on November						
annette masiello						

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

pproved for use through 10/31/202. OMB 0651-0032 ademark Office; U.S. DEPARTMENT OF COMMERCE formation unless it displays valid QMB control number.

correction)

0

FEE TRANSMITTAL **FOR FY 2002**

Patent fees are subject to annual revision.

Name (Print/Type)

Signature

Laurie ∠. Hill

		- C
First Named Inventor	Gregory R. MUNDY, et al.	5.
Examiner Name	R.J. Gitomer	18
Group Art Unit	1627	

09/421,545

October 20, 1999

Application Number

Filing Date

Complete if Known

TOTAL AMOUNT OF PAYMENT (\$) 185.00 Attorney Docket No. 432722002621 METHOD OF PAYMENT **FEE CALCULATION (continued)** The Commissioner is hereby authorized to charge indicated 1. 🗶 fees and credit any overpayments to: 3. ADDITIONAL FEES Deposit Large Entity Small Entity 03-1952 Account Fee Number Fee Fee Code Fee Paid (\$) Code (\$) Fee Description Deposit Account Morrison & Foerster LLP Name 1051 130 205 65 Surcharge - late filing fee or oath × Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 Surcharge - late provisional filing 1052 50 227 25 fee or cover sheet X Applicant claims small entity status. See 37 CFR 1.27 1053 130 130 Non-English specification 2. NOV Payment Enclosed: 1812 For filing a request for ex parte 2.520 147 2,520 reexamination ☐ Check ☐ Credit Card ☐ Money Order ☐ Other Requesting publication of SIR prior 1804 920* 112 9201 to Examiner action **FEE CALCULATION** Requesting publication of SIR after 1805 1,8401 113 1.840 **BASIC FILING FEE** Examiner action 1251 110 215 55 Extension for reply within first month Extension for reply within second 1252 400 216 200 Small Entity month Fee (\$) Fee (\$) Fee Description Extension for reply within third 1253 Code Code 920 **, 460** 217 month 1254 1.440 218 Extension for reply within fourth 720 month 1001 740 201 370 Utility filing fee 1255 1,960 228 980 Extension for reply within fifth month 1002 330 206 165 Design filing fee 1401 320 219 160 Notice of Appeal 1003 510 207 255 Plant filing fee 1402 320 220 160 Filing a brief in support of an appeal 1004 740 208 370 Reissue filing fee 1403 280 221 140 Request for oral hearing 1005 160 214 80 Provisional filing fee 1451 Petition to institute a public use 1,510 138 1.510 proceeding 110 240 55 Petition to revive - unavoidable SUBTOTAL (1) (\$) 0.00 1453 1,280 241 640 Petition to revive - unintentional **EXTRA CLAIM FEES** 1501 1,280 242 640 Utility issue fee (or reissue) Fee from 1502 460 243 230 Design issue fee **Total Claims** - 20** 1503 620 244 310 independent Plant issue fee Claims 1460 130 122 130 Petitions of the Commissioner Multiple Dependent Petitions related to provisional 1807 50 123 50 applications 1806 Submission of Information 180 126 180 Disclosure Stmt Entity Recording each patent assignment Fee Code Fee (\$) Fee Description 8021 (\$) 40 581 40 per properties (times number of 1202 18 Filing a submission after final 203 Claims in excess of 20 1809 740 246 370 rejection (37 CFR § 1.129(a)) 1201 84 202 42 Independent claims in excess of 3 For each additional invention to be 1810 740 249 370 examined (37 CFR § 1.129(b)) 1203 280 Multiple dependent claims, if not paid Request for Continued Examination 1801 740 279 370 (RCE) "Reissue independent claims over 84 209 42 1802 Request for expedited examination 900 169 original patent 900 of a design application "Reissue claims in excess of 20 and 1205 18 210 over original patent Other fee (specify) Terminal Disclaimer under 37 C.F.R. § 3.73(b) SUBTOTAL (2) (\$) 0.00 55 or number previously paid, if greater; For reissues, see above *Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 185.00 SUBMITTED BY Complete (if applicable)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Registration No.

(Attorney/Agent)

51.804

Telephone

Date

(858) 720-7955

November 18, 2002